NEW YORK--(BUSINESS WIRE)--Fera Pharmaceuticals is pleased to announce the launch of Sulfacetamide Sodium Ophthalmic Ointment USP, 10%.
Indicated for superficial ocular infections, including conjunctivitis, Sulfacetamide, in ointment form, will be an important addition to physicians’ treatment armamentarium.
David Cobb, VP of Ophthalmics at Fera says “Fera recognized the need to bring Sulfacetamide Ointment to the market. While doctors have access to Sulfacetamide eye drops, ointments have the advantage of maintaining eye contact time longer, particularly in pediatric patients whose tears may inadvertently wash drops out from the eye. In addition, Sulfacetamide ointment is an important treatment adjunct to the solution, especially at nighttime.”
“Bringing Sulfacetamide Sodium Ophthalmic Ointment to market is very much in keeping with Fera’s vision” says Frank DellaFera, President. “There were other such products available years ago, but their manufacturers decided to discontinue them. We listened to the marketplace and brought it back!”
About Sulfacetamide Sodium Ophthalmic Ointment USP, 10%
Sulfacetamide Sodium Ophthalmic Ointment USP, 10% is contraindicated in patients with hypersensitivity to sulfonamides or to any ingredient of the preparation. FOR TOPICAL EYE USE ONLY-NOT FOR INJECTION. FATALITIES HAVE OCCURRED, ALTHOUGH RARELY, DUE TO SEVERE REACTIONS TO SULFONAMIDES INCLUDING STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, FULMINANT HEPATIC NECROSIS, AGRANULOCYTOSIS, APLASTIC ANEMIA AND OTHER BLOOD DYSCRASIAS. Sensitivity reactions have been reported in individuals with no prior history of sulfonamide hypersensitivity. At the first sign of hypersensitivity, skin rash or other serious reaction, discontinue use of this preparation. Prolonged use of topical anti-bacterial agents may give rise to overgrowth of nonsusceptible organisms including fungi. Bacterial resistance to sulfonamides may also develop. Ophthalmic ointments may retard corneal wound healing. Bacterial and fungal corneal ulcers have been developed during treatment with sulfonamide ophthalmic preparations. The most frequently reported reactions are local irritation, stinging and burning.
Complete prescribing information is available upon request.
About Fera Pharmaceuticals, LLC
Fera Pharmaceuticals is a privately held company. The company goal is to realize opportunities via acquisitions, in-licensing, developing and marketing abbreviated new drug applications (ANDAs), new drug applications (NDAs) and 505(b)(2) NDA products. For more information visit www.ferapharma.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50194433&lang=en